
STALLERGENES GREER ANNOUNCES RESULTS OF 2016 ANNUAL GENERAL MEETING

DATE: June 9, 2016

London (United Kingdom) – Stallergenes Greer plc (the “Company”) announced that, at its Annual General Meeting held earlier today in Paris, France, all resolutions set out in the Notice of Meeting sent to shareholders on 3 May 2016 were duly proposed and passed.

Shareholders re-elected Chairman and CEO Fereydoun Firouz, and Directors Stefan Meister, Jean-Luc Bélingard, Patrick Langlois and Paola Ricci – each for a further term of one year. Three new Board members were also elected, including:

- Rodolfo Bogni as a Non-Executive Director of the Company. Mr. Bogni is Chairman of Northill UK, a director of Waypoint Capital Holdings and a trustee of the Prince of Liechtenstein Foundation and of LGT. He is also a member of the Governing Council of the CSFI (Centre for the Study of Financial Innovation), a member of the Advisory Board of Oxford Analytica and of the Council of Shakespeare’s Globe Theatre.
- Yvonne Schlaepfi, as an Independent Non-Executive Director of the Company. Ms. Schlaepfi is currently Managing Partner and Co-Founder of Stratevise, a Boston-based strategic and transaction advisory firm active in life sciences. She also serves on the External Advisory Council to the Brigham and Women’s Hospital’s largest research-only division, the Channing Division of Network Medicine, and recently served as independent director on the boards of Greer Laboratories and Ares Allergy Holdings (US).
- Elmar Schnee, as an Independent Non-Executive Director of the Company. Mr. Schnee is COO of Mindmaze SA, a neuro-technology company. He is also a member of the Board of Directors of Jazz Pharmaceuticals, and serves currently on the board of directors of four privately held life sciences companies.

“I would like to thank our re-elected Directors, Stefan Meister, Jean-Luc Bélingard, Patrick Langlois and Paola Ricci, for their contribution and advice during this first year for Stallergenes Greer, and our shareholders for their continued support,” said Chairman and CEO, Fereydoun Firouz. *“I am delighted that Rodolfo Bogni, Yvonne Schlaepfi and Elmar Schnee have decided to join our Board of Directors. Each brings significant knowledge and experience in the biopharmaceutical and financial sectors.”*

Mr. Langlois will chair the Audit Committee and Mr. Schnee the Remuneration and Nomination Committees.

The full text of each resolution passed at the Annual General Meeting held earlier today is set out in the Notice of Annual General Meeting which is available for viewing on the Company’s website at www.stallergenesgreer.com.

ABOUT STALLERGENES GREER PLC

Headquartered in London (UK), Stallergenes Greer plc is a global healthcare company specializing in the diagnosis and treatment of allergies through the development and commercialization of allergy immunotherapy products and services. Stallergenes Greer plc is the parent company of GREER Laboratories, Inc. (whose registered office is in the U.S.) and Stallergenes S.A.S. (whose registered office is in France).

Trading information:

Name: Stallergenes Greer

ISIN: GB00BZ21RF93 1 - Ticker: STAGR

ICB classification 4577

Market: Euronext Paris regulated market

Additional information is available at <http://www.stallergenesgreer.com>

This document (including information incorporated by reference in this document), oral statements made and other information published by the Company contain statements that are or may be forward-looking with respect to the financial condition and/or results of operations and businesses of the Company. These statements can be identified by the use of forward-looking terminology such as "believe", "expects", "project", "estimated", "forecast", "should", "plan", "may" or the negative of any of these, or other variations thereof, or comparable terminology indicating expectations or beliefs concerning future events. These forward-looking statements include risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. Without being exhaustive, such factors include economic situations and business conditions, including legal and product evaluation issues, fluctuations in currencies and demand, and changes in competitive factors. These and other factors are more fully described in the Company's 2015 annual report published on 29 April 2016 on the Company's website (www.stallergenesgreer.com). Actual results may differ from those set forth in the forward-looking statements, due to various factors. Save as required by applicable law, neither the Company nor any other person assumes any obligation to update these forward-looking statements or to notify any person of any such update.

Contacts:

Investor and analyst relations

Peter Bühler

Chief Financial Officer

Tel: +33 1 55 59 23 22

Email: investorrelations@aresallergyco.com

Investor relations agency

FTI Consulting

Arnaud de Cheffontaines

Tel: +33 1 47 03 69 48

Email:

arnaud.decheffontaines@fticonsulting.com

Media relations

Lise Lemonnier

Head of Global Communications

Tel: + 33 1 55 59 20 96

Email: llemonnier@stallergenes.com

Media relations agency

Havas Worldwide Paris

Jean-Baptiste Froville

Tel: +33 1 58 47 95 39

Email: jean-baptiste.froville@havasww.com